

Huntington's disease mouse models: unraveling the pathology caused by CAG repeat expansion

Julia Kaye¹ Terry Reisine² Steve Finkbeiner^{1,3,4*}

¹Center for Systems and Therapeutics, Gladstone Institutes, San Francisco, CA, USA

²Independent Scientific Consultant, Santa Cruz, CA, USA

³Taube/Koret Center for Neurodegenerative Disease Research, Gladstone Institutes, San Francisco, CA, USA

⁴Department of Neurology and Physiology, University of California, San Francisco, CA, USA

Abstract

Huntington's disease (HD) is a neurodegenerative disease that results in motor and cognitive dysfunction, leading to early death. HD is caused by an expansion of CAG repeats in the huntingtin gene (*HTT*). Here, we review the mouse models of HD. They have been used extensively to better understand the molecular and cellular basis of disease pathogenesis as well as to provide non-human subjects to test the efficacy of potential therapeutics. The first and best-studied *in vivo* rodent model of HD is the R6/2 mouse, in which a transgene containing the promoter and exon 1 fragment of human *HTT* with 150 CAG repeats was inserted into the mouse genome. R6/2 mice express rapid, robust behavioral pathologies and display a number of degenerative abnormalities in neuronal populations most vulnerable in HD. The first conditional full-length mutant huntingtin (mHTT) mouse model of HD was the bacterial artificial chromosome (BAC) transgenic mouse model of HD (BACHD), which expresses human full-length mHTT with a mixture of 97 CAG-CAA repeats under the control of endogenous *HTT* regulatory machinery. It has been useful in identifying the role of mHTT in specific neuronal populations in degenerative processes. In the knock-in (KI) model of HD, the expanded human CAG repeats and human exon 1 are inserted into the mouse *Htt* locus, so a chimera of the full-length mouse protein with the N-terminal human portion is expressed. Many of aspects of the pathology and behavioral deficits in the KI model better mimic disease characteristics found in HD patients than other models. Accordingly, some have proposed that these mice may be preferable models of the disease over others. Indeed, as our understanding of HD advances, so will the design of animal models to test and develop HD therapies.

Keywords

R6/2 mouse model, BACHD, Huntington's disease, mouse models, neurodegeneration, neurodegenerative disease

Peer Review

The peer reviewers who approve this article are:

1. **Scott Zeitlin**, Department of Neuroscience, University of Virginia School of Medicine, Charlottesville, VA, USA

Competing interests: No competing interests were disclosed.

2. **Irina Dudanova**, Molecular Neurodegeneration Group, Max Planck Institute of Neurobiology, Martinsried, Germany

Competing interests: No competing interests were disclosed.

***Corresponding author:** Steve Finkbeiner (sfinkbeiner@gladstone.ucsf.edu)

Competing interests: The authors declare that they have no competing interests.

Grant information: The funding that supported this work was from National Institutes of Health grant 1 R01 NS101996-01.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2021 Finkbeiner S et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Kaye J, Reisine T and Finkbeiner S. **Huntington's disease mouse models: unraveling the pathology caused by CAG repeat expansion.** Faculty Reviews 2021 **10**:(77) <https://doi.org/10.12703/r/10-77>

Published: 21 Oct 2021, Faculty Reviews **10**:(77) <https://doi.org/10.12703/r/10-77>

Introduction

Huntington's disease (HD) is caused by an expansion of CAG repeats in the huntingtin gene (*HTT*)¹, which leads to neurological deficits, including motor impairment² and cognitive decline³. Normal *HTT* alleles contain fewer than 35 CAG repeats, a CAG repeat of 40 or more is considered a fully penetrant mutation, whereas tracts of 36 to 39 CAGs impart an increased risk of developing the disease⁴⁻⁶. There is a well-established correlation between the number of CAG repeats and age of onset^{7,8}. With extreme CAG expansion, symptoms develop in childhood, pathology is extensive, and life is short. However, CAG repeat length does not fully explain the severity of HD: 30% to 50% of the variation in age of onset is not related to CAG repeat length⁹. Polymorphisms in genes other than *HTT* contribute to age of onset in HD⁹⁻¹². For example, polymorphisms in the FANCI-associated nuclease 1 (*FANL*) gene, which encodes a DNA repair enzyme, affect age of onset of HD¹¹⁻¹³.

In addition to motor and cognitive decline, neuropsychiatric symptoms, including depression and anxiety¹⁴, are present in patients with HD and are thought to typically predate the onset of motor symptoms¹⁵. Other common systemic features of HD include weight loss due to changes in metabolism¹⁶ and sleep and circadian rhythm disturbances¹⁷. Symptoms usually begin in midlife, and death follows within 10 to 20 years¹⁸⁻²⁰.

A prominent neuropathological feature of HD is neurodegeneration, including neuronal death in the striatum, which is a major relay center of cortical signaling through the basal ganglia and is critically involved in regulating motor function and cognition^{21,22}. As a consequence, impaired striatal physiology, including changes at glutamatergic, dopaminergic (DA), and cholinergic synapses, may be evident during the pre-symptomatic phase of HD²³⁻³¹.

Within the striatum, the most prominent neuropathology in HD is the loss of medium spiny-like neurons (MSNs), also known as spiny projection neurons (SPNs), and their cortical pyramidal neuronal innervation^{2,32}. MSNs are the earliest affected neuronal population in HD (Figure 1) and undergo significant loss of dendritic structure and spines with disease progression in humans and animal models³³⁻³⁹. The cortico-striatal neurons are also affected in HD⁴⁰ and impact cognitive decline⁴¹. The polyglutamine stretch in mutant huntingtin (mHTT) causes hyperactivity of glutamatergic cortico-striatal neurons and enhanced striatal glutamatergic transmission, which begins during the asymptomatic phase of HD^{27-29,42} and contributes to synaptic changes observed in later stages (Figure 1). Dysregulated glutamate release at cortico-striatal synapses results in aberrant calcium signaling leading to excitotoxicity and is believed to be one of the causes of MSN vulnerability in HD^{24,28,29}. Genetically reducing mHTT expression selectively in cortico-striatal neurons rescues electrophysiological alterations in striatal MSNs and reduces motor disabilities in mice⁴³. Thus, early in the disease, a hyperactivity of glutamatergic cortico-striatal neurons driven by mHTT expression causes MSN dysfunction, which

may influence the gradual death of striatal neurons over time. Brain imaging studies in pre-symptomatic HD carriers have shown that cortical atrophy occurs early, develops progressively, and correlates with the expression and severity of cognitive and motor symptoms⁴⁴⁻⁴⁶. The loss of cortico-striatal neurons leads to hypoglutamatergic input to the striatum at later stages of the disease. This suggests that the circuitry within the cortico-striatal glutamate neurons and MSNs plays a critical role in striatal dysfunction, MSN death, and HD pathogenesis⁴⁷.

MSNs give rise to two distinct pathways that project to either the substantia nigra pars reticulata (SNr) and internal segment of the globus pallidus (GPI) (the direct pathway) or the external segment of the globus pallidus (GPe), which in turn projects to the subthalamic nucleus (STN)^{48,49} (the indirect pathway). MSNs projecting to the GPe appear to be affected earlier in HD than the other projection pathway and this has been proposed to cause an imbalance in the two pathways and the emergence of involuntary movements and chorea^{50,51}. Whereas MSNs are vulnerable in HD, other striatal neuronal types such as GABA interneurons, including those expressing somatostatin and calretinin, are preserved in the disease⁵². It has been suggested that MSN degeneration may be linked to a loss of neurotrophic support^{53,54} and altered glutamate released from cortico-striatal neurons.

In addition to glutamatergic control, the different MSN projecting neurons are regulated by DA nigrostriatal neurons via activation of either D1 DA receptors or D2 DA receptors. The different populations of striatal MSNs differentially express the receptors; MSNs projecting to the SNr express D1 DA receptors, while MSNs projecting to the GPe primarily express D2 DA receptors^{55,56}. Dopamine released from nigrostriatal neurons diminishes cortico-striatal glutamatergic excitation of the D2-expressing MSN striatopallidal neurons and may be neuroprotective⁵⁷⁻⁵⁹. In contrast, striatal stimulation of D1 DA receptors in MSNs appears to enhance glutamatergic transmission and may contribute to neurodegeneration and neuronal loss in the striatum and MSN-SNr projecting neurons⁶⁰⁻⁶².

Whereas these studies suggest opposing roles of D1 and D2 DA receptors with regard to glutamate toxicity in the striatum, other work has shown that antagonism of both receptors reduces neuronal loss in the striatum⁵⁸ and that blocking D2 receptor stimulation significantly reverses DA potentiation of mHTT-induced MSN cell death⁶³. Consistent with the loss of MSNs in HD, both D1 and D2 DA receptor densities in the striatum are decreased in HD, even in asymptomatic patients, indicating that DA signaling is disrupted in the disease⁶⁴⁻⁶⁶. Striatal D1 and D2 DA receptor densities are also reduced in different animal models of HD⁶⁷⁻⁷⁰. Loss of DA receptors in patients with early-stage HD has been correlated with early cognitive decline⁷¹.

Genetic models have been developed to study both the molecular and cellular basis of HD and to provide systems to identify novel therapeutics, including small-molecule drugs,




Figure 1. Alterations in Neuronal Circuitry in the Basal Ganglia in HD. A) Normal basal ganglia: The direct pathway consists of striatal medium spiny-like neurons (MSNs) expressing D1 dopamine receptors (D1-MSN) that project GABA/substance P (SP) neurons to the internal capsule of the internal globus pallidus (GPI) and the substantia nigra reticulata (SNr). The indirect pathway consists of MSNs expressing D2 dopamine receptors (D2-MSN) that project GABA/Enkephalin (Enk) neurons to the external capsule of the external globus pallidus (GPe) which then projects GABA neurons to the subthalamic nucleus (STN). The STN projects glutamate neurons to the GPI and SNr. The MSNs are innervated by dopamine neurons from the substantia nigra compacta (SNc) and by glutamate neurons from the cortex. The GPI projects inhibitory GABA neurons to the thalamus, and the thalamus projects excitatory glutamate neurons to the cortex. The motor cortex also projects glutamate neurons to the spinal cord to control movement. **B)** Basal ganglia at early stages of Huntington's disease (HD): Cortical glutamate neuronal input to the striatum is hyperactive at early stages of HD, based on animal model work (R6/2 mice). This causes excitotoxicity. D2-MSNs are believed to be more sensitive to the glutamate hyperactivity and begin to degenerate first. The diminished GABA/Enk input to the GPe can produce an imbalance in the basal ganglia function and increase activity in the GPe which subsequently alters activity in the STN. **C)** Basal ganglia at later stages of HD: Both the cortex and striatum show degeneration in later stages of HD. The lost cortical glutamate neurons result in hypoactivity in the striatum. Both the D1-MSNs and the D2-MSNs degenerate.

biologicals, nucleic acids, and cell-based therapeutics to slow progression of the disease. Here, we will focus on the development and use of transgenic mouse models to study HD. We emphasize electrophysiological results that have begun to elucidate mechanisms of neuronal circuit dysfunction that may be related to behavioral deficits in HD.

In vivo HTT transgenic mouse models

R6/2 mouse model of Huntington's disease

The first *in vivo* rodent model of HD to be developed was the R6 line, including the R6/1 and R6/2 models⁷². (See [Table 1](#) for summary of results of mouse models.) The R6/2 mouse model, which is the most widely studied, has a transgene containing the promoter and exon 1 fragment of human *HTT* with 150 CAG repeats inserted into the mouse genome⁷³. The R6/2 model robustly demonstrates the pathological hallmarks of HD, such as motor dysfunction and inclusion body (IB) formation and premature death^{73–76}. The mice survive for about 15 weeks, and mHTT aggregates and inclusions form before the emergence of behavioral phenotypes, which include irregular gait, clasping, weight loss, increased grooming, and cognitive deficits by 5 weeks of age⁷³. As the mice age, they develop seizures. Because of the rapid progression of disease phenotypes, the R6/2 mice have been proposed as a model of juvenile HD.

R6/2 mice display a number of degenerative abnormalities in electrophysiological properties of MSNs and cortico-striatal neurons that may contribute to the rapid appearance and progression of motor and cognitive deficits. The MSNs of symptomatic R6/2 mice have reduced membrane capacitance and increased input resistance, caused by reduced K⁺ channel expression^{24,34,77}. Spontaneous GABA currents and inhibitory post-synaptic currents are increased in R6/2 MSNs^{78,79}, whereas excitatory post-synaptic currents (EPSCs) are decreased^{24,80–82}, which together result in a decrease in burst firing in the striatum.

The electrophysiological properties of the two populations of striatal MSNs—those innervating the SNr and those innervating GPe—are differentially affected in R6/2 mice, resulting in an imbalance in striatal output that may contribute to motor dysfunction⁸³. GABAergic MSNs that innervate the SNr have reduced activity in R6/2 mice, resulting in reduced GABA_A receptor-mediated responses in the SNr and hyperactivity of DA neurons. This hyperactivity may contribute to HD progression⁵⁷. In contrast to the MSNs projecting to the SNr, GABAergic MSNs projecting to the GPe showed increased responses in the GPe. In addition, early on, the cortical pyramidal glutamatergic neurons that project to MSNs become hyperexcitable in R6/2 mice and this enhanced activity precedes behavioral symptoms⁸⁴. This was shown in a study by Burgold *et al.* (2019)⁸⁵, who used chronic *in vivo* two-photon calcium imaging to study neurons in the motor cortex of behaving R6/2 mice. The R6/2 mice showed hyperactivity of the cortical neurons prior to the appearance of motor deficits. Furthermore, Fernández-García *et al.* (2020)⁸⁶ used optogenetic techniques to show that stimulation of

degenerating secondary motor cortex neurons of R6/1 mice that project to the dorsolateral striatum reversed motor deficits and changes in long-term depression and normalized spine density within the striatum. The cortical neurons in the R6/2 mice exhibit decreased synchrony⁸⁷, and synchrony between the cortex, striatum, and STN is disrupted^{88,89}. In addition, glutamate uptake may be impaired⁴⁷. Lack of uptake can lead to an overabundance of synaptic glutamate, which in turn can initiate an excitotoxic neuronal death cascade.

Relatedly, decreased expression of the glutamate transporter 1 (GLT-1) has been reported in the striatum and cortex of postmortem HD brains and R6/2 mice^{90–96}. Studies in R6/2 mice showed that cortical pyramidal neurons are more sensitive to compromised glutamate reuptake and that failure in this system might lead to overactivation of glutamate receptors in the frontal cortex and striatum⁹¹. Interestingly, as frontal cortical pyramidal neurons in the R6/2 mice are more prone to paroxysmal activity, this brain area might be a trigger for the development of epileptic seizures observed in R6/2 mice^{84,97}. GLT-1 is predominantly expressed in astrocytes⁹⁸, suggesting a critical role of astrocytes in neurodegeneration, revealing that the pathology caused by mHTT is not limited to neurons^{99,100}. The rapid progression of phenotypes in R6/2 mice is particularly useful in trying to identify potential disease-modifying agents. Indeed, recent studies using R6/2 mice have revealed a promising cell-based therapy to treat HD using human embryonic stem cell-derived neuronal stem cells (hNSCs)¹⁰¹.

Although the R6/2 model exhibits robust disease-related phenotypes, there are caveats. Primarily, the transgene contains only the first exon of *HTT*; therefore, the protein lacks motifs such as the HEAT domain, through which HTT interacts with other proteins^{102,103}. In addition, this fragment lacks post-translational modification sites that control HTT cleavage and may contribute to toxicity of mHTT^{104–106}. These limitations may explain why the pathological consequences of R6/2 mice differ from those of other transgenic mouse models of HD, described in more detail below.

N171-82Q mouse model of Huntington's disease

Another HD model that expresses an N-terminal fragment of human mHTT is the N171-82Q mouse. The mouse carries a cDNA encoding the N-terminus of human HTT with the initial 171 amino acids and 82 CAG repeats, driven by the mouse prion promoter¹⁰⁷. N171-82Q mice show striatal atrophy and modest MSN degeneration, ventricular enlargement, and a failure to gain weight^{108,109}. They develop tremors, hypokinesia, and lack of coordination. The N171-82Q mice have a more delayed disease onset and longer survival than R6/2 mice¹⁰⁷.

N171-82Q mice also exhibit altered functional neuronal connectivity, as assessed by functional magnetic resonance imaging (fMRI)¹¹⁰. Bilateral connectivity between the motor cortices and somatosensory cortices is reduced in these mice, as is intrastriatal connectivity. The weak intrastriatal connectivity is positively correlated with striatal atrophy and reduced motor

Table 1. Biology of transgenic mice models of Huntington's disease.

Model	Genetic change	Behavioral phenotype	Pathology	Electrophysiology
R6/2 ⁷³	Human exon 1 150 CAG repeats	Cognitive and motor deficits, irregular gait, clasping, weight loss ⁷³⁻⁷⁶ Unique – seizures, early death (15 weeks) ⁷³	IB appear in neurons but death not clearly seen	Cortico-striatal hyperactivity ^{24,34,77-80,82-84,87-89} leads to cortical neurodegeneration ⁵⁷ ↑ striatal D1R medium spiny-like neuron (MSN) activity ⁸³ , ↓ striatal D2R MSN activity, ↑ dopaminergic neuroactivity ⁸³
N171-82Q ⁰⁷	cDNA encoding N-terminal human huntingtin (HTT) – 82 CAG repeats	Tremors, hypokinesia, lack of coordination, no weight gain, no seizures ^{108,109}	Striatal atrophy	Altered cortical and striatal connectivity seen with functional magnetic resonance imaging ¹¹⁰⁻¹¹⁶
YAC ^{117,118}	Full-length human HTT 72/128 CAG repeats All regulatory sites present, similar level of mHTT found as wild-type HTT in controls ¹¹⁸	Symptoms develop at 2–3 months: motor/cognitive deficits, hyperactivity, followed by difficulty in walking, followed by hypoactivity ^{104,117,119}	Striatal and cortical atrophy, selective loss of MSNs ^{104,117,119}	Similar to R6/2 ^{24,26,80,88,89}
BACHD ¹²⁰	Conditional full-length 97 CAG/CAA repeats	Progressive motor deficits start at 2–3 months, hypoactivity in open field, psychiatric symptoms, anxiety in light-dark box, depression–forced swimming ^{70,121,122} Unique: weight gain	Striatal/cortical atrophy at 12 months, ↓ glutamate uptake and astrocyte phenotype, cortical degeneration	Synaptic pathology at 3 months ^{120,123} , cortical interneuronal and parvalbumin ↓ neuronal activity, results in ↑ cortico-striatal activity onto striatal MSNs related to reduced motor function ^{83,123} Reducing mHTT in cortical neurons or MSNs improves synaptic dysfunction and motor functions ¹²⁴ Reduced mHTT in astrocytes improves behavior ¹²⁵
K1 ¹²⁶⁻¹³⁰	Human mutation in mouse gene CAG 140/175	Motor abnormalities, hyperactivity, repetitive movements at 1 month, followed by decreased activity, gait abnormalities subthalamic nucleus (STN) deficits occur prior to striatal dysfunction ^{130,131-134}	Loss of neurons by 2 years, also tyrosine hydroxylase (TH) loss, ↓ thalamic-striatal neurons, olfactory system dysfunction ↓ Spine density of MSNs ^{126,131-133,135-140} By 12 months, 30% STN neurons die ¹⁴¹	↑ GABA current in MSNs, ↓ excitatory post-synaptic currents in MSNs, loss of excitatory input to MSNs, autonomous, STN activity impaired ^{24,28,78,80-82,84,87,142-145}

BACHD, bacterial artificial chromosome (BAC) transgenic mouse model of Huntington's disease; K1, knock-in mouse model with 140 or 175 CAG repeats; N171-82Q, N-terminal fragment of human mutant huntingtin (mHTT) of 171 amino acids and 82 CAG repeats; YAC, yeast artificial chromosome model with 72 or 128 CAG repeats.

function. In these respects, the mice mirror patients with HD, as fMRI also shows altered functional connectivity of cortical and thalamic regions associated with impaired motor function in patients with HD^{111–116}. Reduced intrinsic functional connectivity is present even in premanifest HD gene carriers and to a much larger extent in patients with manifest HD^{111–116}. These studies suggest that mHTT causes disruption of normal neuronal and functional linkage of brain regions involved in motor control and cognition.

YAC72 and YAC128 mouse models of Huntington's disease

The first full-length human mHTT transgenic animal models harbored *HTT* with either 72 or 128 CAG repeats in a yeast artificial chromosome (YAC) that includes all of the human regulatory elements, such as the introns, integrated into the mouse^{117,118}. These models displayed a less severe phenotype than the R6/2 mice and express mHTT at levels similar to endogenous *HTT*¹¹⁸. At about 2 or 3 months of age, the mice develop symptoms, including motor and cognitive deficits that correlate with the appearance of mHTT aggregates and striatal and cortical atrophy^{104,117,119}. The progression of symptoms begins with hyperactivity, followed by difficulty in walking along a rotating rod, and then hypokinesia. Deficits in rotarod performance correlate with loss of striatal neurons¹¹⁷. Many of the electrophysiological abnormalities of the MSNs and cortico-striatal neurons observed in R6/2 mice are similarly found in the YAC128 mice^{24,28,80}. There is also reduced synchrony between the cortex, striatum, and STN in the YAC128 mouse^{88,89}. This is consistent with findings in HD brain showing a progressive disconnect between the cortex and striatum with progression of striatal degeneration^{39,146}.

In 2015, Pancani *et al.* reported that a muscarinic M4 receptor drug reduced the excessive cortical glutamatergic transmission in cortico-striatal slices of YAC128 mice¹⁴⁷. The normalization of glutamate transmission occurred via M4 receptors localized pre-synaptically to the cortical neuronal input. The drug also reduced motor deficits in the mice, suggesting that therapeutics designed to normalize the cortical striatal imbalance might be therapeutically useful.

Furthermore, Al-Gharaibeh *et al.* used the YAC128 model to demonstrate that induced pluripotent stem cell (iPSC)-derived NSCs have the potential as a treatment of HD¹⁴⁸. Mouse iPSC-NSCs bilaterally implanted into the striatum of YAC128 mice differentiated into MSNs and reduced motor deficits. The protective effect of the cells was suggested to be related to their ability to increase levels of brain-derived neurotrophic factor, which supports the survival of remaining neurons in the striatum^{149–151}.

BACHD mouse model of Huntington's disease

The first conditional full-length mHTT mouse model of HD was the bacterial artificial chromosome (BAC) transgenic mouse model of HD (BACHD), which expresses human full-length mHTT with a mixture of 97 CAG and CAA repeats under the control of endogenous *HTT* regulatory machinery¹²⁰. In terms of phenotype, the BACHD model is similar to the YAC128

HD mouse in many ways; progressive motor deficits are apparent as early as 2 months of age, and striatal and cortical atrophy occur at 12 months⁷⁰. BACHD mice display hypoactivity in the open-field test¹²¹ as well as changes in affective behavioral phenotypes such as increased anxiety and depressive behavior at 6 months¹²².

Many of these phenotypes parallel the development of electrophysiological deficits in cortical pyramidal neurons, cortical interneurons, and striatal MSNs. This progressive synaptic pathology occurs around 3 months of age, when the motor deficits are still mild¹²³. Electrophysiological analysis of MSNs of 6-month-old BACHD mice demonstrated selective reduction of large-amplitude EPSCs in striatal neurons¹²⁰. These changes are paralleled by decreased cortical parvalbumin (PV) interneuron excitation and decreased pyramidal cell inhibition, resulting in increased cortico-striatal excitability onto striatal MSNs and a decline in motor function¹²³.

Because synaptic dysfunction in cortico-striatal neurons and striatal MSNs is a critical neurodegenerative process in HD, researchers have used the BACHD mouse to study the effect of mHTT deletion in cortical pyramidal neurons, striatal MSNs, or both⁴³. BACHD mice show significant reductions in *N*-methyl-D-aspartate (NMDA)-evoked synaptic responses in striatal MSNs in slices, and genetically reducing mHTT levels in either cortical pyramidal neurons or MSNs partially reversed this deficit. Furthermore, the MSNs of BACHD mice show reduced activity, indicated by reduced spontaneous EPSCs and increased spontaneous inhibitory post-synaptic currents (IPSCs), and these deficits are ameliorated by reducing mHTT levels in cortical pyramidal neurons. The synaptic deficits were more effectively improved when mHTT was removed from both MSNs and cortical pyramidal neurons. In addition, reducing mHTT levels in cortical neurons also improved neuronal activity in cortical neurons¹²⁴. These findings suggest that mHTT in both cortico-striatal pyramidal neurons and MSNs contributes to synaptic deficits in striatal MSNs.

Removal of mHTT from cortical pyramidal neurons or MSNs partially reversed motor behaviors measured in the rotarod and locomotion tests, but removal of mHTT from both neuronal populations was required to restore these motor behaviors to wild-type control levels⁴³. BACHD mice also exhibit anxiety-like behaviors as measured by light–dark box exploration and depression-like behavior in a forced swimming test. Reducing mHTT in cortico-striatal pyramidal neurons or both cortico-striatal pyramidal neurons and MSNs significantly improved these psychiatric behavioral deficits, whereas mHTT reduction in MSNs alone did not.

These studies suggest that mHTT in striatal MSNs contributes to some aspects of striatal pathogenesis, but the pathogenesis of many behavioral and neurodegenerative phenotypes likely requires mHTT expression in other populations. In particular, dysfunction of cortical pyramidal neurons due to expression of mHTT contributes to synaptic deficits in MSNs and motor and psychiatric behavioral deficits. These findings

indicate distinct but interacting roles of cortical and striatal mHTT in HD pathogenesis and support a role for non-cell-autonomous mHTT toxicity in striatal pathogenesis.

There is also significant evidence that non-neuronal populations contribute to HD¹⁵². The BACHD model was recently used to investigate the role of mHTT in astrocytes on disease phenotypes¹²⁵. That study showed that selective reduction of mHTT in astrocytes in the cortex and striatum improved striatal MSN synaptic responses and behavioral phenotypes. mHTT in astrocytes may contribute to neuronal dysfunction by altering the regulation of extracellular glutamate and other key aspects of synaptic transmission. Altered glutamate release in HD models has been described both *in vitro* and *in vivo*^{110,153}, and impaired glutamate signaling might further occur in HD as a consequence of decreased glutamate uptake. Studies of HD postmortem brain and HD transgenic models have consistently shown decreased GLT-1, which is responsible for the bulk of glutamate uptake in astrocytes^{93–95}. These findings support the role of astrocytes in mHTT-induced HD pathophysiology.

BACHD mice have also been used to study the role of post-translational modifications of mHTT, in particular protein phosphorylation, in disease pathogenesis. Three potential phosphorylation sites—serines 13 and 16 in the N-terminal region and serine 421 in the Akt consensus sequence—were studied^{154,155}. Biochemical studies have shown that phosphorylation at serines 13 and 16 significantly alters the structure of mHTT¹⁵⁵, and phosphorylation at serine 421 alters the transport of mHTT¹⁵⁶, suggesting that post-translational modifications at these sites may affect function of this protein. For the studies in BACHD mice, mHTT constructs were generated in which the serines were converted to aspartates to mimic phosphorylation or to alanine to prevent phosphorylation. The phosphomimetic substitutions were protective and rescued locomotor deficits and anxiety-like behaviors and reduced striatal neuronal loss, whereas the alanine mutations did not hinder the pathogenic actions of mHTT. In the case of the serine 421 site, the phosphomimetic substitution reduced steady-state levels of pathogenic soluble mHTT and increased turnover to improve clearance of mHTT. These studies thus identified specific structural changes in mHTT that may be responsible for pathophysiology in HD.

Knock-in Huntington's disease mouse models

Knock-in (KI) mouse models of HD consist of the human HD mutation inserted into the mouse *HTT* gene locus. Because the mutation is expressed in its appropriate genomic and protein context, these models are believed to more accurately represent the genetic basis of HD and have been used extensively to investigate the pathophysiology of HD and potential treatments¹²⁶. The three KI models that have been studied the most are the Q140, Hdh(CAG)150, and Q175 mice, although other models with varying CAG expansions, including those with 50, 92, and 111 CAG repeats, have also been developed and studied^{157,158}. In the Q140 mice, mouse exon 1 of *HTT* is replaced by a mutated version of human exon 1^{127,128}. Robust

behavioral deficits as well as motor abnormalities have been detected in homozygous CAG140 mice^{128,135,136}. The neuropathology consists of mHTT nuclear staining and aggregates in the striatum and cortex, which become intense and widespread at only 4 months of age. The early pathology corresponds to brain regions that receive DA inputs, supporting the relationship between dopamine and HD pathology^{128,159}. mHTT aggregates are also first seen in the striosomes, consistent with the early vulnerability of this region in humans¹³⁷. These mice also show early loss of thalamic-striatal neuronal input to MSNs, which may contribute to striatal dysfunction manifest as diminished excitatory drive in the striatum¹³⁸. In old age (1–2 years), CAG140 mice show late striatal neuronal loss and atrophy. Surviving neurons express loss of spines and reduced dendritic complexity. The olfactory system displays early and marked aggregate accumulation, which may be relevant to the early deficit in odor discrimination observed in patients with HD^{139,140}.

In the Hdh(CAG)150 model, 150 CAG repeats were inserted into the mouse *HTT* but no human sequences are included¹²⁹. This model shows a delayed onset of symptoms compared with CAG140 mice but exhibit motor defects, such as balance and gait abnormalities, as well as clasping and weight loss, by 40 weeks of age¹³¹. Cognitive deficits occur at around 24 weeks of age¹³². By 22 months, they show widespread mHTT aggregation throughout the brain and transcriptional dysregulation¹⁶⁰.

Interestingly, a study by Arnoux *et al.* (2018)¹⁶¹ using *in vivo* two-photon Ca²⁺ imaging in premanifest Hdh(CAG)150 KI mice showed increased neuronal activity in the visual cortex. This finding is consistent with early signs of hyperactivity in cortical networks found in other HD models and the finding that early in HD the visual cortex is one of the first brain regions to show dysfunction¹⁶².

Side-by-side comparison of CAG140 and Hdh(CAG)150 mice by Franich *et al.* (2019)¹³³ showed that CAG140 mice exhibit earlier onset of behavioral deficits and formation of nuclear inclusions. The authors proposed that these differences may be due to an incompletely spliced *HTT* exon 1 transcript in the CAG140 mouse, which encodes the highly pathogenic exon 1 mHTT protein^{163,164} which leads to early aggregation. The very early phenotypic deficits in the Q140 mice have made them an ideal model for testing novel therapeutic interventions.

The Q175 KI mouse is a spontaneous extension of the Q140 KI¹³⁰. The Q175 KI mouse shows behavioral changes, including motor, cognitive, and circadian deficits¹³⁰. These mice exhibit gait abnormalities at 4 weeks of age, hypoactivity as measured in the open-field test by 4 months^{130,134}, rotarod and climbing abnormalities at 30 weeks of age, and cognitive deficits at 12 months. mHTT aggregates are widely distributed throughout the brain, and the number of neurons containing nuclear inclusions increases with age in both the striatum and cortex¹³⁴. Morphological alterations include decreased numbers of MSNs and striatal volume loss⁸¹.

Both CAG140 and Q175 mice have been used to study synaptic changes caused by mHTT. Within the striatum, there is a decrease in burst firing in CAG140 KI mice^{142,143}, consistent with decreases in EPSCs and increases in IPSCs, much like those found in R6/2 mice^{24,78}. The cortex of CAG140 mice shows increased EPSC frequency⁸⁴ and decreased synchrony⁸⁷. Donzis *et al.* (2020)¹⁶⁵ used two-photon laser-scanning microscopy on symptomatic Q175 mice to study network circuitry in the motor cortical neurons and found that calcium transients had reduced amplitude, suggesting decreased bursting activity. In contrast, in pre-symptomatic Q175 mice, neuronal activity was increased, consistent with a switch in activity of these neurons over time.

Electrophysiological studies have shown that spontaneous GABAergic currents in striatal MSNs are increased in symptomatic Q175 mice⁷⁸ but that EPSCs in MSNs are decreased^{24,80–82} because of alterations in glutamatergic inputs from the cortex and thalamus^{28,78,144}. Significant decreases in spine density of MSNs were found in Q175 mice. The increase in frequency of IPSCs combined with the decrease in frequency of EPSCs generate an imbalance in the ratio of inhibition to excitation, which is relevant for understanding phenotype progression.

This notion is supported by evidence that shows a decline in the glutamate-to-GABA ratio measured by high-performance liquid chromatography in 6-month-old Q175 mice¹⁴¹. Striatal interneurons—both persistent, low threshold-spiking somatostatin-expressing interneurons and fast-firing PV-expressing interneurons—are principal sources of the rise in inhibition seen in MSNs in the R6/2 and BACHD models¹⁶⁶. Loss of excitatory inputs to MSNs, which seem to be associated with loss of dendritic spines and increased inhibitory inputs to MSNs, is exhibited by the Q175 mice.

Studies in R6/2 mice showed that in addition to an alteration of striatal MSN properties, there were changes in output regions of MSNs that may contribute to the pathophysiology of HD. Similarly, Atherton *et al.* showed that in Q175 mice, STN neurons have altered synaptic properties indicative of dysfunction and degeneration¹⁴⁵. The STN is a critical component of the direct and indirect MSNs output pathways and is critical for constraining cortico-striatal activity underlying action selection^{48,167}. In Q175 mice, autonomous STN activity is impaired because of activation of K^{ATP} channels. STN neurons exhibit prolonged NMDA receptor-mediated synaptic currents due to deficient glutamate uptake, which can be rescued by NMDA receptor antagonism. At 12 months of age, about 30% of STN neurons are lost in these mice¹⁴¹. The STN dysfunction and neuronal loss precede striatal cell death and cortico-striatal abnormalities and occur prior to the onset of major behavioral symptoms. Thus, dysfunction and degeneration of cortical and striatal neurons occur in concert with profound changes in other elements of the basal ganglia. Dysfunction within the STN is an early HD feature that may contribute to its expression and course¹⁴⁵.

Interestingly, the availability of KI mouse models with a large range of CAG repeats (50, 92, 111, 140, 150, and 175 CAG repeats) has facilitated studies to establish the relationship between CAG repeat length and the changes in behavior and brain transcription that are linked to the progression of pathogenesis^{168,169}. Similarly, Ament *et al.* (2017)¹⁷⁰ used KI mice with different CAG repeats to begin to understand the molecular basis of CAG repeat instability in the striatum linked to neurodegeneration. Others have also used the KI mice to investigate the role of epigenetic changes that contribute to chromatin remodeling¹⁷¹ and DNA repair alterations in HD^{172,173}.

Conclusions

The development of *in vivo* animal models of HD has greatly added to our understanding of the biology of HD and the molecular and cellular pathways that drive pathogenesis. One issue to consider in the different mouse models is the different forms of mHTT expressed in each. Those with fragments, such as the R6/2 mouse, may produce exaggerated phenotypes and, because the expressed protein lacks downstream regulatory sites, may lack the full range of mutant *HTT* gene and protein-protein interactions. Although the BACHD model has provided important information on structural aspects of the mHTT protein that impact disease behaviors such as locomotion and anxiety, this model is unusual in that the mice gain excessive weight whereas most patients with HD generally have greatly reduced weight. Similarly, the YAC128 mice which express full-length human mHTT also exhibit weight gain. This anomaly may be unrelated to CAG repeat length and has been proposed to be due to the impact of HTT on the expression of IgF-1¹⁷⁴. In the KI model, the expanded human CAG repeats and human exon 1 are inserted into the mouse *Htt* locus, so a chimera of the full-length mouse protein with the N-terminal human portion is expressed. Many aspects of the pathology and behavioral deficits in the Q140 KI mouse and the spontaneously expanded Q175 KI mouse mimic disease characteristics found in patients with HD, and importantly those phenotypes are robust. Accordingly, some have proposed that these mice may be preferable models of the disease¹³³.

The best model is the one that is the most predictive of human disease. Unfortunately, animal models for most human neurodegenerative diseases have historically been poor at predicting which therapeutics are most likely to work in humans. However, as our understanding of the disease mechanisms of HD advances, so will the design of animal models to discover and test innovative therapeutics that may be translated into treatment to slow the onset and progression of HD.

Acknowledgments

We would like to thank Dr. Katy Claiborn (Gladstone Institute, CA), Giovanni Maki (Gladstone Institute, CA), and Dr. Marie-Francoise Chesselet (Emeritus Professor at UCLA, CA) and all members of the Finkbeiner lab.

References



1. MacDonald ME, Ambrose CM, Duyao MP, et al.: **A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.** *Cell.* 1993; **72**(6): 971–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Vonsattel JP, DiFiglia M: **Huntington disease.** *J Neuropathol Exp Neurol.* 1998; **57**(5): 369–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. DiFiglia M, Sapp E, Chase K, et al.: **Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons.** *Neuron.* 1995; **14**(5): 1075–81.
[PubMed Abstract](#) | [Publisher Full Text](#)
4. Bean L, Bayrak-Toydemir P: **American College of Medical Genetics and Genomics Standards and Guidelines for Clinical Genetics Laboratories, 2014 edition: Technical standards and guidelines for Huntington disease.** *Genet Med.* 2014; **16**(12): e2.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Brocklebank D, Gayán J, Andresen JM, et al.: **Repeat instability in the 27-39 CAG range of the HD gene in the Venezuelan kindreds: Counseling implications.** *Am J Med Genet B Neuropsychiatr Genet.* 2009; **150B**(3): 425–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. McNeil SM, Novelletto A, Srinidhi J, et al.: **Reduced penetrance of the Huntington's disease mutation.** *Hum Mol Genet.* 1997; **6**(5): 775–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Snell RG, MacMillan JC, Cheadle JP, et al.: **Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease.** *Nat Genet.* 1993; **4**(4): 393–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Andrew SE, Goldberg YP, Kremer B, et al.: **The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease.** *Nat Genet.* 1993; **4**(4): 398–403.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Wexler NS, Lorimer J, Porter J, et al.: **Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset.** *Proc Natl Acad Sci U S A.* 2004; **101**(10): 3498–503.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Gayán J, Brocklebank D, Andresen JM, et al.: **Genomewide linkage scan reveals novel loci modifying age of onset of Huntington's disease in the Venezuelan HD kindreds.** *Genet Epidemiol.* 2008; **32**(5): 445–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Moss DJH, Pardiñas AF, Langbehn D, et al.: **Identification of genetic variants associated with Huntington's disease progression: A genome-wide association study.** *Lancet Neurol.* 2017; **16**(9): 701–11.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium: **Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease.** *Cell.* 2015; **162**(3): 516–26.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
13. Goold R, Flower M, Moss DH, et al.: **FAN1 modifies Huntington's disease progression by stabilizing the expanded HTT CAG repeat.** *Hum Mol Genet.* 2019; **28**(4): 650–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
14. Anderson KE, Marder KS: **An overview of psychiatric symptoms in Huntington's disease.** *Curr Psychiatry Rep.* 2001; **3**(5): 379–88.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Paoli RA, Botturi A, Ciammola A, et al.: **Neuropsychiatric Burden in Huntington's Disease.** *Brain Sci.* 2017; **7**(6): 67.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Sanberg PR, Fibiger HC, Mark RF: **Body weight and dietary factors in Huntington's disease patients compared with matched controls.** *Med J Aust.* 1981; **1**(8): 407–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Morton AJ, Wood NI, Hastings MH, et al.: **Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease.** *J Neurosci.* 2005; **25**(1): 157–63.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Ross CA, Tabrizi SJ: **Huntington's disease: From molecular pathogenesis to clinical treatment.** *Lancet Neurol.* 2011; **10**(1): 83–98.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Myers RH: **Huntington's disease genetics.** *NeuroRx.* 2004; **1**(2): 255–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Roos RA: **Huntington's disease: A clinical review.** *Orphanet J Rare Dis.* 2010; **5**: 40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Crossman AR: **Functional anatomy of movement disorders.** *J Anat.* 2000; **196**(Pt 4): 519–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Graybiel AM, Aosaki T, Flaherty AW, et al.: **The basal ganglia and adaptive motor control.** *Science.* 1994; **265**(5180): 1826–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
23. Walker FO: **Huntington's Disease.** *Semin Neurol.* 2007; **27**(2): 143–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Cepeda C, Hurst RS, Calvert CR, et al.: **Transient and Progressive Electrophysiological Alterations in the Corticostriatal Pathway in a Mouse Model of Huntington's Disease.** *J Neurosci.* 2003; **23**(3): 961–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. DiProspero NA, Chen EY, Charles V, et al.: **Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements.** *J Neurocytol.* 2004; **33**(5): 517–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. André VM, Cepeda C, Venegas A, et al.: **Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease.** *J Neurophysiol.* 2006; **95**(4): 2108–19.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Graham RK, Pouladi MA, Joshi P, et al.: **Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease.** *J Neurosci.* 2009; **29**(7): 2193–204.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Joshi PR, Wu NP, André VM, et al.: **Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease.** *J Neurosci.* 2009; **29**(8): 2414–27.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Milnerwood AJ, Gladding CM, Pouladi MA, et al.: **Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice.** *Neuron.* 2010; **65**(2): 178–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Faculty Opinions Recommendation](#)
30. Kipps CM, Duggins AJ, Mahant N, et al.: **Progression of structural neuropathology in preclinical Huntington's disease: A tensor based morphometry study.** *J Neurol Neurosurg Psychiatry.* 2005; **76**(5): 650–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Starling AJ, André VM, Cepeda C, et al.: **Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease.** *J Neurosci Res.* 2005; **82**(3): 377–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. de La Monte SM, Vonsattel JP, Richardson EP Jr: **Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease.** *J Neuropathol Exp Neurol.* 1988; **47**(5): 516–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Ferrante RJ, Kowall NW, Richardson EP Jr: **Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: A combined study using the section-Golgi method and calbindin D28k immunocytochemistry.** *J Neurosci.* 1991; **11**(12): 3877–87.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Klapstein GJ, Fisher RS, Zanjani H, et al.: **Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice.** *J Neurophysiol.* 2001; **86**(6): 2667–77.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Laforet GA, Sapp E, Chase K, et al.: **Changes in Cortical and Striatal Neurons Predict Behavioral and Electrophysiological Abnormalities in a Transgenic Murine Model of Huntington's Disease.** *J Neurosci.* 2001; **21**(23): 9112–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. Marco S, Giralt A, Petrovic MM, et al.: **Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models.** *Nat Med.* 2013; **19**(8): 1030–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Spires TL, Grote HE, Garry S, et al.: **Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice.** *Eur J Neurosci.* 2004; **19**(10): 2799–807.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Wu J, Ryskamp DA, Liang X, et al.: **Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model.** *J Neurosci.* 2016; **36**(1): 125–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Cepeda C, Wu N, André VM, et al.: **The corticostriatal pathway in Huntington's disease.** *Prog Neurobiol.* 2007; **81**(5–6): 253–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. Tan B, Shishegar R, Poudel GR, et al.: **Cortical morphometry and neural dysfunction in Huntington's disease: A review.** *Eur J Neurol.* 2021; **28**(4): 1406–19.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Faculty Opinions Recommendation](#)
41. Langley C, Gregory S, Osborne-Crowley K, et al.: **Fronto-striatal circuits for cognitive flexibility in far from onset Huntington's disease: Evidence from the Young Adult Study.** *J Neurol Neurosurg Psychiatr.* 2021; **92**(2): 143–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)

42. André VM, Cepeda C, Fisher YE, *et al.*: **Differential electrophysiological changes in striatal output neurons in Huntington's disease.** *J Neurosci.* 2011; **31**(4): 1170–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43.  Wang N, Gray M, Lu XH, *et al.*: **Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease.** *Nat Med.* 2014; **20**(5): 536–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
44. Rosas HD, Koroshetz WJ, Chen YI, *et al.*: **Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis.** *Neurology.* 2003; **60**(10): 1615–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
45. Rosas HD, Hevelone ND, Zaleta AK, *et al.*: **Regional cortical thinning in preclinical Huntington disease and its relationship to cognition.** *Neurology.* 2005; **65**(5): 745–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
46. Rosas HD, Tuch DS, Hevelone ND, *et al.*: **Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures.** *Mov Disord.* 2006; **21**(9): 1317–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
47. Estrada-Sánchez AM, Rebec GV: **Role of cerebral cortex in the neuropathology of Huntington's disease.** *Front Neural Circuits.* 2013; **7**: 19.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
48. Albin RL, Young AB, Penney JB: **The functional anatomy of basal ganglia disorders.** *Trends Neurosci.* 1989; **12**(10): 366–75.
[PubMed Abstract](#) | [Publisher Full Text](#)
49. Gerfen CR, Engber TM, Mahan LC, *et al.*: **D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.** *Science.* 1990; **250**(4986): 1429–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Reiner A, Albin RL, Anderson KD, *et al.*: **Differential loss of striatal projection neurons in Huntington disease.** *Proc Natl Acad Sci U S A.* 1988; **85**(15): 5733–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
51. Albin RL, Reiner A, Anderson KD, *et al.*: **Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease.** *Ann Neurol.* 1992; **31**(4): 425–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
52.  Holley SM, Kamdjou T, Reidling JC, *et al.*: **Therapeutic effects of stem cells in rodent models of Huntington's disease: Review and electrophysiological findings.** *CNS Neurosci Ther.* 2018; **24**(4): 329–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
53. Zuccato C, Ciammola A, Rigamonti D, *et al.*: **Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease.** *Science.* 2001; **293**(5529): 493–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
54. Zuccato C, Cattaneo E: **Role of brain-derived neurotrophic factor in Huntington's disease.** *Prog Neurobiol.* 2007; **81**(5–6): 294–330.
[PubMed Abstract](#) | [Publisher Full Text](#)
55. Gerfen CR, Surmeier DJ: **Modulation of striatal projection systems by dopamine.** *Annu Rev Neurosci.* 2011; **34**: 441–66.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
56.  Kravitz AV, Freeze BS, Parker PRL, *et al.*: **Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry.** *Nature.* 2010; **466**(7306): 622–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
57. Cepeda C, Murphy KPS, Parent M, *et al.*: **The role of dopamine in Huntington's disease.** *Prog Brain Res.* 2014; **211**: 235–54.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
58. Bozzi Y, Borrelli E: **Dopamine in neurotoxicity and neuroprotection: What do D₂ receptors have to do with it?** *Trends Neurosci.* 2006; **29**(3): 167–74.
[PubMed Abstract](#) | [Publisher Full Text](#)
59. Cepeda C, Colwell CS, Itri JN, *et al.*: **Dopaminergic modulation of NMDA-induced whole cell currents in neostriatal neurons in slices: Contribution of calcium conductances.** *J Neurophysiol.* 1998; **79**(1): 82–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
60. Wang JQ, Chen Q, Wang X, *et al.*: **Dysregulation of mitochondrial calcium signaling and superoxide flashes cause mitochondrial genomic DNA damage in Huntington disease.** *J Biol Chem.* 2013; **288**(5): 3070–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
61. Tang TS, Chen X, Liu J, *et al.*: **Dopaminergic signaling and striatal neurodegeneration in Huntington's disease.** *J Neurosci.* 2007; **27**(30): 7899–910.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
62. Paoletti P, Vila I, Rife M, *et al.*: **Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: The role of p25/cyclin-dependent kinase 5.** *J Neurosci.* 2008; **28**(40): 10090–101.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
63. Charvin D, Roze E, Perrin V, *et al.*: **Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo.** *Neurobiol Dis.* 2008; **29**(1): 22–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
64. Richfield EK, O'Brien CF, Eskin T, *et al.*: **Heterogeneous dopamine receptor changes in early and late Huntington's disease.** *Neurosci Lett.* 1991; **132**(1): 121–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
65. van Oostrom JCH, Dekker M, Willemsen ATM, *et al.*: **Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease.** *Eur J Neurol.* 2009; **16**(2): 226–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
66. Weeks RA, Piccini P, Harding AE, *et al.*: **Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease.** *Ann Neurol.* 1996; **40**(1): 49–54.
[PubMed Abstract](#) | [Publisher Full Text](#)
67. Cha JH, Kosinski CM, Kerner JA, *et al.*: **Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene.** *Proc Natl Acad Sci U S A.* 1998; **95**(11): 6480–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
68. Bibb JA, Yan Z, Svenningsson P, *et al.*: **Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice.** *Proc Natl Acad Sci U S A.* 2000; **97**(12): 6809–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
69. Ariano MA, Aronin N, DiFiglia M, *et al.*: **Striatal neurochemical changes in transgenic models of Huntington's disease.** *J Neurosci Res.* 2002; **68**(6): 716–29.
[PubMed Abstract](#) | [Publisher Full Text](#)
70. Pouladi MA, Stanek LM, Xie Y, *et al.*: **Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice.** *Hum Mol Genet.* 2012; **21**(10): 2219–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
71. Bäckman L, Farde L: **Dopamine and cognitive functioning: Brain imaging findings in Huntington's disease and normal aging.** *Scand J Psychol.* 2001; **42**(3): 287–96.
[PubMed Abstract](#) | [Publisher Full Text](#)
72. Sathasivam K, Hobbs C, Mangiarini L, *et al.*: **Transgenic models of Huntington's disease.** *Philos Trans R Soc Lond B Biol Sci.* 1999; **354**(1386): 963–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
73. Mangiarini L, Sathasivam K, Seller M, *et al.*: **Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice.** *Cell.* 1996; **87**(3): 493–506.
[PubMed Abstract](#) | [Publisher Full Text](#)
74. Li JY, Popovic N, Brundin P: **The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.** *NeuroRx.* 2005; **2**(3): 447–64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
75. Carter RJ, Lione LA, Humby T, *et al.*: **Characterization of Progressive Motor Deficits in Mice Transgenic for the Human Huntington's Disease Mutation.** *J Neurosci.* 1999; **19**(8): 3248–57.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
76. Gourfinkel-An I, Parain K, Hartmann A, *et al.*: **Changes in GAD₆₇ mRNA expression evidenced by *in situ* hybridization in the brain of R6/2 transgenic mice.** *J Neurochem.* 2003; **86**(6): 1369–78.
[PubMed Abstract](#) | [Publisher Full Text](#)
77. Ariano MA, Cepeda C, Calvert CR, *et al.*: **Striatal potassium channel dysfunction in Huntington's disease transgenic mice.** *J Neurophysiol.* 2005; **93**(5): 2565–74.
[PubMed Abstract](#) | [Publisher Full Text](#)
78. Cepeda C, Starling AJ, Wu N, *et al.*: **Increased GABAergic function in mouse models of Huntington's disease: Reversal by BDNF.** *J Neurosci Res.* 2004; **78**(6): 855–67.
[PubMed Abstract](#) | [Publisher Full Text](#)
79. Dvorzhak A, Semter M, Faber DS, *et al.*: **Tonic mGluR5/CB1-dependent suppression of inhibition as a pathophysiological hallmark in the striatum of mice carrying a mutant form of huntingtin.** *J Physiol.* 2013; **591**(4): 1145–66.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
80. Cummings DM, Cepeda C, Levine MS: **Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington's disease.** *ASN Neuro.* 2010; **2**(3): e00036.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
81. Heikkinen T, Lehtimäki K, Vartiainen N, *et al.*: **Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease.** *PLoS One.* 2012; **7**(12): e50717.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
82. Indersmitten T, Tran CH, Cepeda C, *et al.*: **Altered excitatory and inhibitory inputs to striatal medium-sized spiny neurons and cortical pyramidal neurons in the Q175 mouse model of Huntington's disease.** *J Neurophysiol.* 2015; **113**(7): 2953–66.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
83.  Barry J, Akopian G, Cepeda C, *et al.*: **Striatal Direct and Indirect Pathway**

- Output Structures Are Differentially Altered in Mouse Models of Huntington's Disease.** *J Neurosci.* 2018; **38**(20): 4678–94.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
84. Cummings DM, André VM, Uzgil BO, *et al.*: **Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease.** *J Neurosci.* 2009; **29**(33): 10371–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
85.  Burgold J, Schulz-Trieglaff EK, Voelkl K, *et al.*: **Cortical circuit alterations precede motor impairments in Huntington's disease mice.** *Sci Rep.* 2019; **9**(1): 6634.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
86.  Fernández-García S, Conde-Berriozabal S, García-García E, *et al.*: **M2 cortex-dorsolateral striatum stimulation reverses motor symptoms and synaptic deficits in Huntington's disease.** *eLife.* 2020; **9**: e57017.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
87. Walker AG, Miller BR, Fritsch JN, *et al.*: **Altered information processing in the prefrontal cortex of Huntington's disease mouse models.** *J Neurosci.* 2008; **28**(36): 8973–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
88. Hong SL, Cossyleon D, Hussain WA, *et al.*: **Dysfunctional behavioral modulation of corticostriatal communication in the R6/2 mouse model of Huntington's disease.** *PLoS One.* 2012; **7**(10): e47026.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
89. Callahan JW, Abercrombie ED: **Age-dependent alterations in the cortical entrainment of subthalamic nucleus neurons in the YAC128 mouse model of Huntington's disease.** *Neurobiol Dis.* 2015; **78**: 88–99.
[PubMed Abstract](#) | [Publisher Full Text](#)
90. Estrada-Sánchez AM, Montiel T, Segovia J, *et al.*: **Glutamate toxicity in the striatum of the R6/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters.** *Neurobiol Dis.* 2009; **34**(1): 78–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
91.  Estrada-Sánchez AM, Castro D, Portillo-Ortiz K, *et al.*: **Complete but not partial inhibition of glutamate transporters exacerbates cortical excitability in the R6/2 mouse model of Huntington's disease.** *CNS Neurosci Ther.* 2019; **25**(4): 509–18.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
92. Arzberger T, Krampfl K, Leimgruber S, *et al.*: **Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease--an in situ hybridization study.** *J Neuropathol Exp Neurol.* 1997; **56**(4): 440–54.
[PubMed Abstract](#) | [Publisher Full Text](#)
93. Liévens JC, Woodman B, Mahal A, *et al.*: **Impaired glutamate uptake in the R6 Huntington's disease transgenic mice.** *Neurobiol Dis.* 2001; **8**(5): 807–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
94. Behrens PF, Franz P, Woodman B, *et al.*: **Impaired glutamate transport and glutamate-glutamine cycling: Downstream effects of the Huntington mutation.** *Brain.* 2002; **125**(Pt 8): 1908–22.
[PubMed Abstract](#) | [Publisher Full Text](#)
95. Hassel B, Tessler S, Faull RLM, *et al.*: **Glutamate uptake is reduced in prefrontal cortex in Huntington's disease.** *Neurochem Res.* 2008; **33**(2): 232–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
96. Faideau M, Kim J, Cormier K, *et al.*: **In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: A correlation with Huntington's disease subjects.** *Hum Mol Genet.* 2010; **19**(15): 3053–67.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
97. Cepeda-Prado E, Popp S, Khan U, *et al.*: **R6/2 Huntington's disease mice develop early and progressive abnormal brain metabolism and seizures.** *J Neurosci.* 2012; **32**(19): 6456–67.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
98. Danbolt NC: **Glutamate uptake.** *Prog Neurobiol.* 2001; **65**(1): 1–105.
[PubMed Abstract](#) | [Publisher Full Text](#)
99.  Skotte NH, Andersen JV, Santos A, *et al.*: **Integrative Characterization of the R6/2 Mouse Model of Huntington's Disease Reveals Dysfunctional Astrocyte Metabolism.** *Cell Rep.* 2018; **23**(7): 2211–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Faculty Opinions Recommendation](#)
100. Khakh BS, Beaumont V, Cacho R, *et al.*: **Unravelling and Exploiting Astrocyte Dysfunction in Huntington's Disease.** *Trends Neurosci.* 2017; **40**(7): 422–37.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
101.  Reidling JC, Relaño-Ginés A, Holley SM, *et al.*: **Human Neural Stem Cell Transplantation Rescues Functional Deficits in R6/2 and Q140 Huntington's Disease Mice.** *Stem Cell Reports.* 2018; **10**(1): 58–72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
102.  Guo Q, Huang B, Cheng J, *et al.*: **The cryo-electron microscopy structure of huntingtin.** *Nature.* 2018; **555**(7694): 117–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
103. Andrade MA, Bork P: **HEAT repeats in the Huntington's disease protein.** *Nat Genet.* 1995; **11**(2): 115–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
104. Ehrnhoefer DE, Butland SL, Pouladi MA, *et al.*: **Mouse models of Huntington disease: Variations on a theme.** *Dis Model Mech.* 2009; **2**(3–4): 123–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
105. Cattaneo E, Zuccato C, Tartari M: **Normal huntingtin function: An alternative approach to Huntington's disease.** *Nat Rev Neurosci.* 2005; **6**(12): 919–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
106. Ehrnhoefer DE, Sutton L, Hayden MR: **Small changes, big impact: Posttranslational modifications and function of huntingtin in Huntington disease.** *Neuroscientist.* 2011; **17**(5): 475–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
107. Schilling G, Becher MW, Sharp AH, *et al.*: **Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin.** *Hum Mol Genet.* 1999; **8**(3): 397–407.
[PubMed Abstract](#) | [Publisher Full Text](#)
108. Yu ZX, Li SH, Evans J, *et al.*: **Mutant Huntingtin Causes Context-Dependent Neurodegeneration in Mice with Huntington's Disease.** *J Neurosci.* 2003; **23**(6): 2193–202.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
109. Gardian G, Browne SE, Choi DK, *et al.*: **Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease.** *J Biol Chem.* 2005; **280**(1): 556–63.
[PubMed Abstract](#) | [Publisher Full Text](#)
110. Li Q, Li G, Wu D, *et al.*: **Resting-state functional MRI reveals altered brain connectivity and its correlation with motor dysfunction in a mouse model of Huntington's disease.** *Sci Rep.* 2017; **7**: 16742.
[Publisher Full Text](#)
111. Wolf RC, Sambataro F, Vasic N, *et al.*: **Abnormal resting-state connectivity of motor and cognitive networks in early manifest Huntington's disease.** *Psychol Med.* 2014; **44**(15): 3341–56.
[PubMed Abstract](#) | [Publisher Full Text](#)
112. Harrington DL, Rubinov M, Durgarian S, *et al.*: **Network topology and functional connectivity disturbances precede the onset of Huntington's disease.** *Brain.* 2015; **138**(Pt 8): 2332–46.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
113. Koenig KA, Lowe MJ, Harrington DL, *et al.*: **Functional connectivity of primary motor cortex is dependent on genetic burden in prodromal Huntington disease.** *Brain Connect.* 2014; **4**(7): 535–46.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
114. Dumas EM, van den Bogaard SJA, Hart EP, *et al.*: **Reduced functional brain connectivity prior to and after disease onset in Huntington's disease.** *Neuroimage Clin.* 2013; **2**: 377–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
115. van den Stock J, de Winter FL, Ahmad R, *et al.*: **Functional brain changes underlying irritability in premanifest Huntington's disease.** *Hum Brain Mapp.* 2015; **36**(7): 2681–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
116. Sánchez-Castañeda C, de Pasquale F, Caravasso CF, *et al.*: **Resting-state connectivity and modulated somatomotor and default-mode networks in Huntington disease.** *CNS Neurosci Ther.* 2017; **23**(6): 488–97.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
117. Slow EJ, van Raamsdonk J, Rogers D, *et al.*: **Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease.** *Hum Mol Genet.* 2003; **12**(13): 1555–67.
[PubMed Abstract](#) | [Publisher Full Text](#)
118. Hodgson JG, Agopyan N, Gutekunst CA, *et al.*: **A YAC Mouse Model for Huntington's Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration.** *Neuron.* 1999; **23**(1): 181–92.
[PubMed Abstract](#) | [Publisher Full Text](#)
119. van Raamsdonk JM, Pearson J, Slow EJ, *et al.*: **Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease.** *J Neurosci.* 2005; **25**(16): 4169–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
120. Gray M, Shirasaki DI, Cepeda C, *et al.*: **Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice.** *J Neurosci.* 2008; **28**(24): 6182–95.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
121. Menalled L, El-Khodori BF, Patry M, *et al.*: **Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models.** *Neurobiol Dis.* 2009; **35**(3): 319–36.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
122. Hult Lundh S, Nilsson N, Soylu R, *et al.*: **Hypothalamic expression of mutant huntingtin contributes to the development of depressive-like behavior in the BAC transgenic mouse model of Huntington's disease.** *Hum Mol Genet.* 2013; **22**(17): 3485–97.
[PubMed Abstract](#) | [Publisher Full Text](#)

123. Spampinato J, Gu X, Yang XW, *et al.*: **Progressive synaptic pathology of motor cortical neurons in a BAC transgenic mouse model of Huntington's disease.** *Neuroscience*. 2008; **157**(3): 606–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
124. Estrada-Sánchez AM, Burroughs CL, Cavaliere S, *et al.*: **Cortical efferents lacking mutant huntingtin improve striatal neuronal activity and behavior in a conditional mouse model of Huntington's disease.** *J Neurosci*. 2015; **35**(10): 4440–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
125. Wood TE, Barry J, Yang Z, *et al.*: **Mutant huntingtin reduction in astrocytes slows disease progression in the BACHD conditional Huntington's disease mouse model.** *Hum Mol Genet*. 2019; **28**(3): 487–500.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
126. Menalled LB: **Knock-in mouse models of Huntington's disease.** *NeuroRx*. 2005; **2**(3): 465–70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
127. Hickey MA, Chesselet MF: **Apoptosis in Huntington's disease.** *Prog Neuropsychopharmacol Biol Psychiatry*. 2003; **27**(2): 255–65.
[PubMed Abstract](#) | [Publisher Full Text](#)
128. Menalled LB, Sison JD, Dragatsis I, *et al.*: **Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats.** *J Comp Neurol*. 2003; **465**(1): 11–26.
[PubMed Abstract](#) | [Publisher Full Text](#)
129. Lin CH, Tallaksen-Greene S, Chien WM, *et al.*: **Neurological abnormalities in a knock-in mouse model of Huntington's disease.** *Hum Mol Genet*. 2001; **10**(2): 137–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
130. Menalled LB, Kudwa AE, Miller S, *et al.*: **Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: ZQ175.** *PLoS One*. 2012; **7**(12): e49838.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
131. Heng MY, Tallaksen-Greene SJ, Detloff PJ, *et al.*: **Longitudinal evaluation of the Hdh(CAG)150 knock-in murine model of Huntington's disease.** *J Neurosci*. 2007; **27**(34): 8989–98.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
132. Brooks SP, Betteridge H, Trueman RC, *et al.*: **Selective extra-dimensional set shifting deficit in a knock-in mouse model of Huntington's disease.** *Brain Res Bull*. 2006; **69**(4): 452–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
133. Franich NR, Hickey MA, Zhu C, *et al.*: **Phenotype onset in Huntington's disease knock-in mice is correlated with the incomplete splicing of the mutant huntingtin gene.** *J Neurosci Res*. 2019; **97**(12): 1590–605.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
134. Peng Q, Wu B, Jiang M, *et al.*: **Characterization of Behavioral, Neuropathological, Brain Metabolic and Key Molecular Changes in zQ175 Knock-In Mouse Model of Huntington's Disease.** *PLoS One*. 2016; **11**(2): e0148839.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
135. Dorner JL, Miller BR, Barton SJ, *et al.*: **Sex differences in behavior and striatal ascorbate release in the 140 CAG knock-in mouse model of Huntington's disease.** *Behav Brain Res*. 2007; **178**(1): 90–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
136. Rising AC, Xu J, Carlson A, *et al.*: **Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats.** *Exp Neurol*. 2011; **228**(2): 173–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
137. Lerner RP, Trejo Martinez LDCG, Zhu C, *et al.*: **Striatal atrophy and dendritic alterations in a knock-in mouse model of Huntington's disease.** *Brain Res Bull*. 2012; **87**(6): 571–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
138. Deng YP, Wong T, Bricker-Anthony C, *et al.*: **Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington's disease mice.** *Neurobiol Dis*. 2013; **60**: 89–107.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
139. Lasic SE, Goodman AOG, Grote HE, *et al.*: **Olfactory abnormalities in Huntington's disease: Decreased plasticity in the primary olfactory cortex of R6/1 transgenic mice and reduced olfactory discrimination in patients.** *Brain Res*. 2007; **1151**: 219–26.
[PubMed Abstract](#) | [Publisher Full Text](#)
140. Bylsma FW, Moberg PJ, Doty RL, *et al.*: **Odor identification in Huntington's disease patients and asymptomatic gene carriers.** *J Neuropsychiatry Clin Neurosci*. 1997; **9**(4): 598–600.
[PubMed Abstract](#) | [Publisher Full Text](#)
141. Smith GA, Rocha EM, McLean JR, *et al.*: **Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease.** *Hum Mol Genet*. 2014; **23**(17): 4510–27.
[PubMed Abstract](#) | [Publisher Full Text](#)
142. Miller BR, Walker AG, Shah AS, *et al.*: **Dysregulated information processing by medium spiny neurons in striatum of freely behaving mouse models of Huntington's disease.** *J Neurophysiol*. 2008; **100**(4): 2205–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
143. Miller J, Arrasate M, Brooks E, *et al.*: **Identifying polyglutamine protein species *in situ* that best predict neurodegeneration.** *Nat Chem Biol*. 2011; **7**(12): 925–34.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
144. Kolodziejczyk K, Raymond LA: **Differential changes in thalamic and cortical excitatory synapses onto striatal spiny projection neurons in a Huntington disease mouse model.** *Neurobiol Dis*. 2016; **86**: 62–74.
[PubMed Abstract](#) | [Publisher Full Text](#)
145. Atherton JF, McIver EL, Mullen MR, *et al.*: **Early dysfunction and progressive degeneration of the subthalamic nucleus in mouse models of Huntington's disease.** *eLife*. 2016; **5**: e21616.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
146. Miller BR, Bezprozvanny I: **Corticostriatal circuit dysfunction in Huntington's disease: Intersection of glutamate, dopamine and calcium.** *Future Neurol*. 2010; **5**(5): 735–56.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
147. Pancani T, Foster DJ, Moehle MS, *et al.*: **Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice.** *Proc Natl Acad Sci U S A*. 2015; **112**(45): 14078–83.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
148. Al-Gharraibeh A, Culver R, Stewart AN, *et al.*: **Induced Pluripotent Stem Cell-Derived Neural Stem Cell Transplants Reduce Behavioral Deficits and Ameliorated Neuropathological Changes in YAC128 Mouse Model of Huntington's Disease.** *Front Neurosci*. 2017; **11**: 628.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
149. Dey ND, Bombard MC, Roland BP, *et al.*: **Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington's disease.** *Behav Brain Res*. 2010; **214**(2): 193–200.
[PubMed Abstract](#) | [Publisher Full Text](#)
150. Serrano-Sanchez JA, Lera-Navarro A, Dorado-García C, *et al.*: **Contribution of individual and environmental factors to physical activity level among Spanish adults.** *PLoS One*. 2012; **7**(6): e38693.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
151. Pollock K, Dahlenburg H, Nelson H, *et al.*: **Human Mesenchymal Stem Cells Genetically Engineered to Overexpress Brain-derived Neurotrophic Factor Improve Outcomes in Huntington's Disease Mouse Models.** *Mol Ther*. 2016; **24**(5): 965–77.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
152. Gray M: **Astrocytes in Huntington's Disease.** *Adv Exp Med Biol*. 2019; **1175**: 355–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Faculty Opinions Recommendation](#)
153. Nicnocaill B, Haraldsson B, Hansson O, *et al.*: **Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice.** *Eur J Neurosci*. 2001; **13**(1): 206–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
154. Gu X, Greiner ER, Mishra R, *et al.*: **Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice.** *Neuron*. 2009; **64**(6): 828–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
155. Kratter IH, Zahed H, Lau A, *et al.*: **Serine 421 regulates mutant huntingtin toxicity and clearance in mice.** *J Clin Invest*. 2016; **126**(9): 3585–97.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
156. Zala D, Colin E, Rangone H, *et al.*: **Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons.** *Hum Mol Genet*. 2008; **17**(24): 3837–46.
[PubMed Abstract](#) | [Publisher Full Text](#)
157. Wheeler VC, Auerbach W, White JK, *et al.*: **Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse.** *Hum Mol Genet*. 1999; **8**(1): 115–22.
[PubMed Abstract](#) | [Publisher Full Text](#)
158. Wheeler VC, White JK, Gutekunst CA, *et al.*: **Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice.** *Hum Mol Genet*. 2000; **9**(4): 503–13.
[PubMed Abstract](#) | [Publisher Full Text](#)
159. Menalled LB, Sison JD, Wu Y, *et al.*: **Early Motor Dysfunction and Striosomal Distribution of Huntingtin Microaggregates in Huntington's Disease Knock-In Mice.** *J Neurosci*. 2002; **22**(18): 8266–76.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
160. Kuhn A, Goldstein DR, Hodges A, *et al.*: **Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.** *Hum Mol Genet*. 2007; **16**(15): 1845–61.
[PubMed Abstract](#) | [Publisher Full Text](#)
161. Arnoux I, Willam M, Griesche N, *et al.*: **Metformin reverses early cortical network dysfunction and behavior changes in Huntington's disease.** *eLife*. 2018; **7**: e38744.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)

162. Labuschagne I, Cassidy AM, Scahill RI, *et al.*: **Visuospatial Processing Deficits Linked to Posterior Brain Regions in Premanifest and Early Stage Huntington's Disease.** *J Int Neuropsychol Soc.* 2016; **22**(6): 595–608.
[PubMed Abstract](#) | [Publisher Full Text](#)
163. Neueder A, Landles C, Ghosh R, *et al.*: **The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington's disease patients.** *Sci Rep.* 2017; **7**(1): 1307.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
164. Sathasivam K, Neueder A, Gipson TA, *et al.*: **Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease.** *Proc Natl Acad Sci U S A.* 2013; **110**(6): 2366–70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
165.  Donzis EJ, Estrada-Sánchez AM, Indersmitten T, *et al.*: **Cortical Network Dynamics Is Altered in Mouse Models of Huntington's Disease.** *Cereb Cortex.* 2020; **30**(4): 2372–88.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
166. Cepeda C, Galvan L, Holley SM, *et al.*: **Multiple sources of striatal inhibition are differentially affected in Huntington's disease mouse models.** *J Neurosci.* 2013; **33**(17): 7393–406.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
167. Oldenburg IA, Sabatini BL: **Antagonistic but Not Symmetric Regulation of Primary Motor Cortex by Basal Ganglia Direct and Indirect Pathways.** *Neuron.* 2015; **86**(5): 1174–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
168. Langfelder P, Cantle JP, Chatzopoulou D, *et al.*: **Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice.** *Nat Neurosci.* 2016; **19**(4): 623–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
169. Alexandrov V, Brunner D, Menalled LB, *et al.*: **Large-scale phenome analysis defines a behavioral signature for Huntington's disease genotype in mice.** *Nat Biotechnol.* 2016; **34**(8): 838–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
170. Ament SA, Pearl JR, Grindeland A, *et al.*: **High resolution time-course mapping of early transcriptomic, molecular and cellular phenotypes in Huntington's disease CAG knock-in mice across multiple genetic backgrounds.** *Hum Mol Genet.* 2017; **26**(5): 913–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
171.  Alcalá-Vida R, Seguin J, Lotz C, *et al.*: **Age-related and disease locus-specific mechanisms contribute to early remodelling of chromatin structure in Huntington's disease mice.** *Nat Commun.* 2021; **12**(1): 364.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
172.  Morozko EL, Smith-Geater C, Monteys AM, *et al.*: **PIAS1 modulates striatal transcription, DNA damage repair, and SUMOylation with relevance to Huntington's disease.** *Proc Natl Acad Sci U S A.* 2021; **118**(4): e2021836118.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
173.  Maiuri T, Hung CLK, Suart C, *et al.*: **DNA Repair in Huntington's Disease and Spinocerebellar Ataxias: Somatic Instability and Alternative Hypotheses.** *J Huntingtons Dis.* 2021; **10**(1): 165–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
174. Pouladi MA, Xie Y, Skotte NH, *et al.*: **Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression.** *Hum Mol Genet.* 2010; **19**(8): 1528–38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)